Earnings summaries and quarterly performance for CURIS.
Executive leadership at CURIS.
Board of directors at CURIS.
Research analysts who have asked questions during CURIS earnings calls.
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for CRIS
Also covers: AFMD, ALXO, ARVN +7 more
DB
Danya Ben-Hail
JonesTrading Institutional Services
2 questions for CRIS
EW
Edward White
H.C. Wainwright & Co.
2 questions for CRIS
Also covers: DVAX, GLYC, IKT +5 more
Sean McCutcheon
Raymond James
2 questions for CRIS
Also covers: BMY, CMPX, CYTK +6 more
AL
Anna Lee
Truist
1 question for CRIS
BJ
Billal Jahangiri
Truist Securities
1 question for CRIS
DB
Daniel Bronder
Cantor Fitzgerald
1 question for CRIS
Also covers: ASND
NG
Nicole Germino
Truist Securities
1 question for CRIS
Also covers: GILD, INSM, SGMO +1 more
SN
Sara Nik
H.C. Wainwright & Co., LLC
1 question for CRIS
Also covers: CDTX, LSTA, PHGE
SR
Soumit Roy
JonesTrading
1 question for CRIS
Also covers: AVXL, CMRX, DAWN +4 more
SD
Srikripa Devarakonda
Truist Financial Corporation
1 question for CRIS
Also covers: ABCL, ABSI, AFMD +12 more
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
1 question for CRIS
Also covers: AFMD, ALDX, ARCT +13 more
Recent press releases and 8-K filings for CRIS.
Curis Closes Private Placement
CRIS
- Curis, Inc. announced the closing of its previously announced private placement (PIPE financing).
- The private placement generated gross proceeds of up to $80.8 million for the Company, with initial gross proceeds of approximately $20.2 million.
- The financing included participation from Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP, as well as other new and existing institutional investors and company insiders.
Jan 9, 2026, 1:00 PM
Curis Announces Pricing of Private Placement
CRIS
Convertible Preferred Issuance
Delisting/Listing Issues
- Curis, Inc. announced the pricing of a private placement (PIPE financing) expected to generate up to $80.8 million in gross proceeds, including initial gross proceeds of approximately $20.2 million.
- The financing involves the sale of Series B convertible preferred stock and Series A, B, and C warrants, with an exercise price of $0.75 per share for the warrants, to new and existing institutional investors and company insiders.
- The company intends to use the initial net proceeds, along with existing cash, for research and development, general corporate expenses, and working capital, which is expected to extend its cash runway into 2027.
- Curis believes the proceeds from this PIPE financing will help it maintain stockholders' equity above the $2.5 million requirement for continued Nasdaq listing, addressing previous delisting concerns.
Jan 8, 2026, 12:50 AM
Curis Announces Private Placement for Up to $80.8 Million
CRIS
Convertible Preferred Issuance
New Projects/Investments
- Curis, Inc. announced a private placement (PIPE financing) expected to generate up to $80.8 million in gross proceeds, including initial gross proceeds of approximately $20.2 million, before placement agent fees and offering expenses.
- The financing involves the sale of 20,195 shares of Series B convertible non-redeemable preferred stock and Series A, B, and C warrants to purchase 26,926,675 shares of Common Stock each, with a warrant exercise price of $0.75 per share.
- Investors in the PIPE financing include new and existing healthcare-focused institutional investors, as well as company insiders such as the Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Chief Development Officer, and a board member.
- The company plans to use the initial net proceeds, along with existing cash, to fund research and development, general corporate expenses, and working capital needs.
- The PIPE financing is expected to close on or about January 8, 2026.
Jan 7, 2026, 1:45 PM
Curis Provides Updated Clinical Data for AML Triplet Study
CRIS
New Projects/Investments
Profit Warning
Delisting/Listing Issues
- Curis, Inc. presented updated clinical data from its frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) at the 67th ASH Annual Meeting on December 9, 2025.
- As of October 12, 2025, 5 of 8 patients (62.5%) in the study achieved Undetectable MRD (uMRD), an increase from 4 of 8 patients (50%) reported on July 2, 2025.
- The study evaluates adding emavusertib to venetoclax and azacitidine in AML patients who remain MRD-positive after achieving complete remission.
- Curis's CEO, James Dentzer, described the updated data as "very promising" and warranting further evaluation.
- The company disclosed it will require substantial additional capital to fund its business and does not have sufficient cash to support current operations within the next 12 months from the press release date.
Dec 9, 2025, 1:00 PM
Curis Reports Q3 2025 Financial Results and Provides Clinical Program Updates
CRIS
Earnings
Guidance Update
New Projects/Investments
- Curis reported a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2025, an improvement compared to a net loss of $10.1 million, or $1.70 per share, for the same period in 2024. Research and development expenses decreased to $6.4 million in Q3 2025 from $9.7 million in Q3 2024.
- As of September 30, 2025, Curis's cash and cash equivalents were $9.1 million, with approximately 12.7 million shares of common stock outstanding. The company believes its existing cash will fund operations into 2026 and plans to raise additional capital prior to the end of the year.
- Progress continues in the Take-Aim lymphoma study evaluating emavusertib in primary CNS lymphoma, with plans to enroll additional patients over the next 12-18 months to support accelerated submissions in the U.S. and Europe.
- A new proof-of-concept study for emavusertib in CLL patients is expected to enroll its first patient in late Q4 2025 or early Q1 2026, with initial data anticipated at the December 2026 ASH annual meeting.
- Initial data from the AML triplet study showed MRD conversion to undetectable levels in 4 of 8 evaluable patients as of July 2, 2025.
Nov 6, 2025, 9:30 PM
Curis Reports Q3 2025 Results, Advances Clinical Pipeline, and Sells Erivedge Business
CRIS
Earnings
M&A
Delisting/Listing Issues
- Curis, Inc. reported a net loss of $7.7 million or $0.49 per share on $3.2 million in revenues for the third quarter ended September 30, 2025.
- The company advanced its clinical pipeline, continuing enrollment in the TakeAim Lymphoma study for PCNSL and initiating a Phase 2 study for CLL, with the first patient expected in late Q4 2025 or early Q1 2026.
- On November 6, 2025, Curis sold its Erivedge Business for $2.5 million upfront and a release of future royalty liabilities, which means the company will no longer be entitled to revenues under the Erivedge License Agreement.
- As of September 30, 2025, Curis held $9.1 million in cash and cash equivalents, which is projected to fund operations into the first quarter of 2026. The company is also addressing a Nasdaq delisting notice, believing the Erivedge sale may help meet an alternative listing requirement.
Nov 6, 2025, 9:01 PM
Curis Reports Third Quarter 2025 Financial and Operational Results
CRIS
Earnings
Guidance Update
New Projects/Investments
- Curis reported a net loss of $7.7 million or $0.49 per share and revenues of $3.2 million for the third quarter ended September 30, 2025.
- As of September 30, 2025, cash and cash equivalents totaled $9.1 million, which is expected to fund operations into the first quarter of 2026. This cash runway was extended by a recently completed registered direct offering and private placement.
- The company made progress advancing clinical studies in PCNSL, CLL, and AML, including enrolling PCNSL patients for accelerated approval filings and initiating a Phase 2 study in CLL with the first patient expected in late Q4 2025 or early Q1 2026.
- Curis plans to present clinical data for PCNSL and SCNSL at the SNO annual meeting in November, and initial data from the frontline AML triplet study at the ASH annual meeting in December.
Nov 6, 2025, 9:00 PM
Curatis Reports H1 2025 Financials and Positive FDA Meeting for C-PTBE-01
CRIS
Earnings
Guidance Update
New Projects/Investments
- Curatis Holding AG reported revenue of 5.2 million CHF for the first half of 2025, marking a 14% year-over-year growth compared to Curatis AG's revenue in the same period of 2024.
- The company recorded a loss of 1.2 million CHF for the period, primarily due to increased development expenses for its main product candidate, C-PTBE-01 (corticorelin).
- Curatis held a positive Type B meeting with the US FDA on September 9, 2025, to discuss the design of a pivotal Phase 3 clinical trial for C-PTBE-01, and has initiated the process to find global pharmaceutical partners for the product in Q3 2025.
- The company expanded its product portfolio through a partnership with Phoenix Labs, adding four products that generated approximately 5 million CHF in revenue in 2024.
- Curatis Group anticipates revenue growth in 2025 and aims to reach break-even in 2026 through increased revenues and cost reductions.
Sep 15, 2025, 2:32 PM
Curatis Reports H1 2025 Results and Positive FDA Meeting for C-PTBE-01
CRIS
Earnings
Guidance Update
New Projects/Investments
- Curatis Holding AG reported CHF 5.2 million in revenue for the first half of 2025, marking a 14% growth compared to the previous year, but recorded a loss of CHF -1.2 million primarily due to increased development expenses for C-PTBE-01.
- The company established a partnership with Phoenix Labs, adding four products that generated nearly CHF 5 million in revenue in 2024.
- Curatis held a positive Type-B meeting with the US FDA on September 9, 2025, to align on the design of the crucial Phase 3 clinical trial for its main drug candidate, C-PTBE-01 (Corticorelin).
- Curatis anticipates revenue growth for 2025 compared to 2024 and aims to achieve break-even in 2026, driven by new product introductions and the ongoing search for C-PTBE-01 partners.
Sep 15, 2025, 2:32 PM
Curatis Reports H1 2025 Financials and Positive FDA Meeting for C-PTBE-01
CRIS
Earnings
Guidance Update
New Projects/Investments
- Curatis reported H1 2025 revenues of CHF 5.2m, reflecting a 14% like-for-like year-over-year growth in its distribution business, while incurring a loss of CHF -1.2m primarily due to increased development expenses for C-PTBE-01.
- The company announced a positive outcome from its Type B meeting with the US FDA on September 9, 2025, regarding its lead product candidate, C-PTBE-01 (corticorelin).
- A new partnership with Phoenix Labs, Ireland, added four products that generated approximately CHF 5m in revenues in 2024, which is expected to drive revenue growth in 2025.
- Curatis holds a cash position of CHF 2.0m and has set an objective to achieve a break-even result in 2026.
Sep 15, 2025, 5:00 AM
Quarterly earnings call transcripts for CURIS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more